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Abstract. Pharmaceutical aerosols have been targeted to the lungs for the treatment of asthma and
pulmonary infectious diseases successfully. Micafungin (Astellas Pharma US, Deerfield, IL, USA) has
been shown to be an effective antifungal agent when administrated intravenously. Pulmonary delivery of
micafungin has not previously been reported. In the present pilot study, we characterize the performance
of two nebulizers and their potential for delivering micafungin to the lungs as well as the use of
multivariate data analysis for mass distribution profile comparison. The concentration of micafungin
sodium increased by 21% when delivered by the Acorn II nebulizer and by 20% when delivered by the
LC Plus nebulizer, respectively, from the first to the second sampling period. The Acorn II nebulizer
delivered a fine particle fraction FPF5.8 (%<5.8 μm) of 92.5±0.8 and FPF3.3 (%<3.3 μm) of 82.3±2.1
during the first sampling period. For the LC Plus nebulizer, FPF5.8 was 92.3±0.1 and FPF3.3 was 67.0±0.7
during the first sampling period. The mass median aerodynamic diameter (MMAD) increased from
1.67±0.05 to 1.77±0.04 μm (Acorn II nebulizer) and from 2.09±0.01 to 2.20±0.01 μm (Pari LC Plus
nebulizer) from the first to the second sampling periods. These changes in MMAD were statistically
significant by paired t test. Multivariate data analysis showed that this could be explained systematically
by greater drug deposition on stages with larger cutoff sizes and reduced drug deposition on stages with
smaller cutoff sizes rather than multimodal deposition or other anomalies in size distribution.
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INTRODUCTION
Micafungin sodium is an echinocandin antifungal agent
(1) that was approved by the United States Food and Drug
Administration in March 2005. The drug has been proven
effective for prophylaxis against candidal infections in
patients undergoing hematopoietic stem cell transplantation
and for the treatment of esophageal candidiasis and invasive
candidiasis (2). Micafungin was synthesized from a natural
product of the fungus Coleophama empedri by certain
modifications to improve its potency (3). Micafungin acts as
a noncompetitive inhibitor of the enzyme, 1,3-β-D-glucan
synthase, an enzyme unique to fungi which is necessary for
synthesis of 1,3-β-D-glucan. 1,3-β-D-Glucan is essential for
osmotic stability and integrity of the cell wall of several
common fungal pathogens (4,5). Micafungin exhibits fungi-
static activity against Aspergillus spp. but is fungicidal against
Candida spp., which may be explained by the difference in
the relative abundance of 1,3-β-D-glucan in the fungal cell
wall of the fungi (6–8). Due to large molecular weight and
poor oral bioavailability, micafungin can only be administered
intravenously. Pharmacokinetic studies of micafungin suggest
a linear dose-dependent relationship (9) in both pediatric and
adult patients with a half-life of 14.6±3 h (10). Micafungin is
widely distributed into various tissue including liver, kidney,
and lung tissues as demonstrated in rat and rabbit models
(11,12). The drug utilizes biliary excretion as its primary route
of elimination and is, therefore, not a concern when used in
patients with renal dysfunction (2).
Aerosol delivery of drugs has been widely adopted
especially in asthma therapy and has been studied for many
agents including corticosteroids, bronchodilators, antibiotics,
and antifungal agents (13,14). Delivery devices include
propellant-driven metered dose inhalers (pMDIs), dry powder
inhalers (DPIs), and nebulizers (15). Nebulizers are used to
administer drugs in the form of a liquid mist to the airways.
Large quantities of drug can be administrated in this manner
compared to pMDIs and DPIs. In contrast to pMDIs and DPIs
which administrate bolus doses of drugs, nebulizers deliver
drugs in a continuous manner. Aerosol delivery of drugs can
achieve greater local concentrations in the lung, which is
frequently the site by which many pathogens gain entry into
the body. The wisdom regarding aerosol delivery of antimicro-
bials lies in the potential to deliver high concentrations of drug
that exceed the inhibitory concentrations for target pathogens
directly to the site of initial colonization and subsequent
infection, the lung. The quantity of drug delivered may exceed
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attainable pulmonary concentrations when the drug is admin-
istered systemically. Drugs delivered by the pulmonary route
may or may not help treat systemic infection depending on the
capacity to achieve adequate plasma concentration for therapy
by this route of administration. In some instances, low or
nondetectable plasma concentrations may be desirable in
order to avoid systemic drug toxicities from prophylactic
regimens or in patients with localized infections.
Lung delivery requires a particle size in the range of 1–5 μm
(13,15). Therefore, mass distribution profiles of aerosols, which
are used to derive mass median aerodynamic diameter
(MMAD) and fine particle fraction (FPF), are of great interest
to the investigators. The Product Quality Research Institute
(PQRI) working group has expended significant effort in
pursuing a profile comparator for aerosol particle size distribu-
tion (APSD) of pharmaceutical aerosols (16–18). The chi-
square test has been proposed to serve as a statistical test for
judging equivalence between reference and test profiles.
However, this test was not recommended by the PQRI working
group after intensive investigation (17). Principal component
analysis (PCA) and orthogonal partial least square analysis
(OPLS) have been employed frequently in the field of
metabolomics mainly because of their ability to deal with very
large data sets (19–21).However, their ability to compareAPSD
profiles has not been studied previously. PCA and OPLS may
serve as powerful tools for individual judgment of equivalence
of APSD profiles, while further effort is needed to study their
potential as a general APSD profile comparator.
As part of the first phase of a clinical program to investigate
aerosolized micafungin as a prophylactic agent for pulmonary
infections, a comparison of different nebulizer systems is
needed. The purpose of this study was to generate mass
distribution profiles of aerosolized micafungin using two differ-
ent nebulizers and to assess PCA and OPLS as methods for
comparing the APSD profiles generated. Based on these data,
three nebulizer candidates for clinical use will be evaluated in
the future to determine the ideal device for micafungin delivery.
MATERIALS AND METHODS
Nebulizers and Drug
Acorn II (Marquest, Englewood, CO, USA) and LC Plus
(Pari, Midlothian, VA, USA) nebulizers were driven by com-
pressed air at a flow rate of 8 L/min. Micafungin (Astellas
Pharma US, Deerfield, IL, USA), as supplied by the manufac-
turer, was dilutedwith 5mLNaCl (0.9%) to a final concentration
of approximately 10 mg/mL for nebulization. Drug analysis was
performed byUV spectrophotometry at a maximum absorbance
of 270 nm. Excipients present in micafungin include lactose and
citric acid, which have no absorbance at this wavelength. A
calibration curve was obtained with R2=0.9995.
Particle Size Analysis
Mass median aerodynamic diameter (in micrometers)
was calculated at two sampling periods using stage deposition
data obtained from an Andersen cascade impactor (Ambient,
1ACFM nonviable, eight-stage sampler; Andersen, Smyrna,
GA, USA) operated at a vacuum flow rate of 28.3 L/min. A
short interval of sampling was used to avoid overloading the
stages. Nebulizers were first operated for 2 min for Acorn II
and 1 min for LC Plus and aerosol generated was directed to
the cascade impactor. Then nebulization was stopped and
nebulizers were stored at 4°C until the next operation. Both
nebulizers were operated for another period of 4 min without
directing the aerosol into the cascade impactor. After this,
Acorn II and LC Plus nebulizers were operated again for
another 2 and 1 min, respectively, with aerosols directed into
a cascade impactor. All nebulization was carried out after the
solution in the reservoir reached ambient temperature to
eliminate temperature effect on mass distribution. FPF was
calculated as the ratio of the mass deposited on stages below
a certain cutoff size to the total amount of mass recovered.
The geometric standard deviation (GSD) was calculated as
the square root of the ratio of P84 (particle size under which
84% of the total mass was achieved in the cumulative mass
distribution) to P16 (22).
Effect of Nebulization on the Concentration of Micafungin
Sodium
At the beginning and after each 2-min nebulization
interval, a 50 μL sample was withdrawn from the reservoir
and stored in a 20-mL glass vial wrapped with aluminum foil.
After collecting all samples, 14.95 mL of 20 mM KH2PO4 was
added to each vial to bring the total volume up to 15 mL. The
concentration of micafungin sodium was calculated from UV
spectrophotometry data.
Statistical Analysis
Paired t test was used to compare MMAD from the two
different sampling periods. OPLS was employed to compare
percent mass distribution profiles within each nebulizer. PCA
was employed to compare profiles between two nebulizers.
Paired t test was carried out in Minitab 14.1 (Minitab). OPLS
and PCAwere carried out in SIMCA-P 11.5 (Umetrics). Data
were pretreated with mean-centering and unit-variance
scaling before executing OPLS and PCA.
RESULTS
Mass Distribution from Two Nebulizers
The percent mass APSD profiles of micafungin sodium
are shown in Fig. 1. Very little drug was deposited in the
throat and inlet during sampling. Most deposition occurred
on stage 5 (1.1 μm) and stage 4 (2.1 μm) for both Acorn II
and LC Plus nebulizers. A significant difference between
APSD profiles generated from the two nebulizers was
observed visually. Compared with the profile from the Acorn
II nebulizer, there was significantly greater mass deposited on
stage 2 (4.7 μm) and stage 3 (3.3 μm) with the LC Plus
nebulizer. Profile change from the first sampling period to the
second was also observed.
Effect of Nebulizers and Nebulization Time on Aerosol
Property
Mass median aerodynamic diameter, GSD, and FPF
were all calculated and are tabulated in Table I. The mass
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deposited in the cascade impactor follows log-normal distri-
bution and GSD was thus calculated. The MMAD derived
from Acorn II was smaller than that derived from LC Plus.
The MMAD from the first nebulization was smaller than that
from the second nebulization for both Acorn II and LC Plus
nebulizers. This observation is statistically different by paired
t test (Acorn II, p=0.015; LC Plus, p=0.011). Paired t test was
justified for this comparison since the experiment was
designed in such a way that both the first and second
nebulizations were carried out from one parent solution and
the same nebulizer. FPF3.3 (%<3.3 μm) for the Acorn II is
significantly higher than that for the LC Plus. However, this
difference was not observed for FPF5.8 (%<5.8 μm).
Effect of Nebulization Time on Drug Concentration
The concentration of micafungin sodium increased
continuously with duration of nebulization for both nebulizers
(Fig. 2). The concentration in the LC Plus increased more
rapidly than that of theAcorn II nebulizer. A quadratic function
was employed to fit data points withR2>0.99 for both regression
analyses. Compared with the initial concentration, the final
concentration of micafungin sodium increased by 48% with the
Acorn II nebulizer and by 40% with the LC Plus nebulizer.
From the first to the second sampling period, the concentration
of micafungin sodium increased by 21% with the Acorn II
nebulizer compared with 20% with the LC Plus nebulizer.
Multivariate Data Analysis for Profile Comparison
OPLS was used for profile comparison within each
nebulizer. The goodness of OPLS model fit (R2) is 0.889 for
Acorn II nebulizer and 0.921 for LC Plus nebulizer. The
predictive power of OPLS model (Q2) is 0.807 for Acorn II
and 0.808 for LC Plus nebulizer. Each data point in the scores
plot (Fig. 3) represents a percent mass distribution profile
obtained from a single experiment. As shown, mass profiles of
Fig. 1. Percent mass APSD of micafungin sodium measured by
Andersen cascade impactor. a Micafungin was delivered via Acorn II
nebulizer and measured at 0–2 and 6–8 min, respectively. b Micafungin
was delivered via LC Plus nebulizer and measured at 0–1 and 5–6 min,
respectively. Each bar represents the mean±SEM (n=3)
Table I. Effect of nebulizers and nebulization time on particle size and distribution (MMAD, μm, and GSD) and fine particle fraction (FPF%









MMAD (μm) 1.67±0.05 1.77±0.04 2.09±0.01 2.20±0.01
GSD 2.28±0.01 2.27±0.03 2.13±0.02 2.18±0.01
FPF (%<3.3 μm) 82.3±2.1 79.1±1.1 67.0±0.7 64.8±0.8
FPF (%<5.8 μm) 92.5±0.8 91.9±0.3 92.3±0.1 91.1±1.3
n=3, mean±SEM
MMAD mass median aerodynamic diameter, GSD geometric standard deviation, FPF fine particle fraction
Fig. 2. Effects of nebulization time on the concentration of micafun-
gin sodium. The concentration of micafungin sodium in the reservoir
was measured by UV spectrophotometry at different time points after
nebulization. Each data point represents the mean±SEM (n=3). A
quadratic function was employed to fit in data points
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the first nebulization period were easily discriminated from that
of the second period as marked by the different colored ellipses.
The loadings plot (Fig. 4) suggested variables which were
responsible for the patterns seen in the scores plot. As shown in
Fig. 4a, deposition on stages 7 and 6 (0.4 and 0.7 μm,
respectively) and stages 2, 3, 0, and 4 (4.7, 3.3, 9.0, and 2.1 μm,
respectively) account for the separation of two sets of profiles
(first vs. second nebulization) for the Acorn II nebulizer.
Deposition on stage 5 (1.1 μm), filter, and stage 1, 0 (5.8 and
9.0 μm) account for the separation of two sets of profiles (first vs.
second nebulization) for the LC Plus nebulizer.
The relative importance and confidence interval for each
variable that contributed to the profile separation is plotted in
Fig. 5. Variables with the largest absolute mean value and the
smallest confidence intervals are most important, accounting
for profile separation. A conclusion regarding which variables
were responsible for the patterns seen in the scores plot could
also be reached from the contribution plot.
We further studied the APSD profiles by pooling all of
the profiles from Acorn II and LC Plus nebulizers. PCA was
used to find pattern in these profiles (Fig. 6). Without a priori
knowledge of the identity of each profile, PCA clearly
Fig. 3. Scores plot from OPLS analysis of percent mass APSD profiles obtained from two nebulization
periods. a Micafungin was nebulized by Acorn II nebulizer. b Micafungin was nebulized by LC Plus
nebulizer. The blue ellipse includes three data points from the first nebulization period and the red ellipse
includes three data points from the second nebulization period
132 Shi, Dodds Ashley, Alexander and Hickey
discriminated between them. A pattern could be seen with
profiles from LC Plus nebulizers clustered to the left side of
the scores plot (Fig. 6a) and profiles from Acorn II nebulizers
located to the right side. Furthermore, a separation could be
seen for profiles from Acorn II nebulizer of different
nebulization periods. No such separation could be seen for
LC Plus nebulizer. The loadings plot (Fig. 6b) showed the
influential variables that contributed to the pattern seen in
the scores plot (Fig. 6a).
DISCUSSION
Intravenous infusion is the only route that has been
approved for the administration of micafungin to patients. To
our knowledge, there is no published data on the use of
aerosolized micafungin for the prevention or treatment of
invasive fungal infection. This is the first description of the
characteristics of a micafungin aerosol. Aerosolized micafun-
gin may be particularly attractive for several reasons: (1)
Fig. 4. Loadings plot from OPLS analysis of percent mass APSD profiles obtained from two nebulization
periods. a Micafungin was nebulized by Acorn II nebulizer. b Micafungin was nebulized by LC Plus
nebulizer. Blue and red ellipses mark the cascade impactor positions where mass deposition of micafungin
sodium changed significantly from the first nebulization period to the second nebulization period
133Initial Characterization of Micafungin Pulmonary Delivery
targeting micafungin to the lung may result in improved
efficacy and reduced toxicity; (2) aerosolized micafungin may
potentially attain higher concentrations in the epithelial lining
fluid and upper airways than can be achieved by intravenous
infusion; (3) targeted pulmonary delivery via nebulization may
alleviate the need for intravenous infusion; and (4) the
duration of administration may be significantly shortened
given theminimum 1 h intravenous infusion time for this agent.
We noticed that there was a small increase in the
MMAD from the first nebulization period to the second for
both nebulizers. This modest increase in the MMAD may be
explained by the increased concentration of micafungin,
which results from evaporation during nebulization. Large
surface areas were formed by nebulization, which greatly
accelerates evaporation by mass transfer from aqueous phase
to gas phase (23,24). The concentration change of micafungin
between the two nebulization periods corresponds relatively
well to the change in MMAD based on simple calculations.
Although this small increase in MMAD was statistically
significant, it may not be clinically important since both
MMADs fall within the desired range. FPF5.8 for both
nebulizers exceeded 90%, which indicates that a significant
Fig. 5. Contribution plot from OPLS analysis of percent mass APSD profiles obtained from two
nebulization periods. Error bar represents the confidence interval
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proportion of nebulized droplets can reach peripheral lungs.
The flow rate used in these studies was in the recommended
ranges for each nebulizer; no efforts were made to optimize
delivery conditions for the nebulizers.
Although the paired t test could be used to detect the
differences in MMAD, this parameter is a derivative from
mass distribution profiles. Important information could be
lost if MMAD is the only parameter assessed. A profile
comparison method should be used to consider APSDs as a
whole rather than focusing on MMAD. Candidate methods
include t test, chi-square test (16), and PCA. Multiple t tests
with Bonferroni correction may be considered for profile
comparison. However, multiple comparisons will result in
inflation of type I error, the error of rejecting a null
hypothesis when it is actually true. Bonferroni correction
may control the overall error rate; however, it was considered
too stringent to reject the null hypothesis.
Other correction methods may also be employed,
although there is currently no consensus about which
correction method is the best. Chi-square test has been
intensively investigated as a tool for comparison of APSD
of aerosolized drug formulations. However, it was not
recommended for APSD profile comparison for several
reasons. The main concern for the chi-square test is that it
Fig. 6. PCA of percent mass APSD profiles from Acorn II and LC Plus nebulizers. a Scores plot with the
first two components (A indicates Acorn II nebulizer; L LC Plus; first two digits nebulization period; last
digit experiment number). b Loadings plot with the first two components. Variables that contribute to the
separation in the scores plot could be found correspondingly in the loadings plot
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fails to detect the difference among profiles when a difference
does exist (16–18). In this study, we propose another method
for APSD profile comparison for the following reasons: (1)
APSD profile is multidimensional, having approximately ten
predictive variables; (2) the masses deposited on each stage
are not totally independent (16,17); and (3) the tool should
not only be able to detect the difference, but also pinpoint the
origin of the difference.
OPLS and PCA can reduce multiple dimensions into one
or two major components. The issue of covariance among
predictive variables could also be solved by these two
methods since new components are all orthogonal. Moreover,
the scores plot of PCA and OPLS could provide an overall
pattern of APSD profiles studied. If a particular pattern was
observed, the influential variables that contribute to the
pattern could be found in the corresponding loadings plot.
In the present study, we performed OPLS for APSD
profile comparison within each nebulizer. A pattern (the
separation of profiles from two nebulization periods) was
observed in the scores plot. Furthermore, this separation can
be explained by the loading and contribution plots, indicating
that greater drug was deposited on plates with larger cutoff
sizes and reduced drug deposition on plates with smaller
cutoff sizes from the first nebulization period to the second
one. Although several stages contributed to the separation,
we should first focus on the most influential stages where
confidence is highest.
PCA was performed for APSD profiles comparison
between two nebulizers. PCA is different from OPLS in that
a priori knowledge of the identity of the profiles is not
employed while patterns are assessed. It is usually a good
practice to perform PCA before proceeding to OPLS. From
Fig. 6, a clear pattern could be seen. Profiles from the Acorn
II nebulizer were completely separated from the profiles of
the LC Plus nebulizer. And the separation among profiles
from the two nebulization periods of Acorn II nebulizer could
also be seen. In contrast, no such separation was observed for
LC Plus nebulizer. A possible explanation is that PCA places
the first component onto between-nebulizer difference (largest
difference) and the second component onto within-nebulizer
difference of Acorn II nebulizer (second largest difference).
However, the within-nebulizer difference of LC Plus nebulizer
is relatively small compared to the above differences and may
be represented by a successive component, which was not
shown in the figure.
One potential application for PCA andOPLS is to evaluate
cascade impactor profiles in general for pharmaceutical aero-
sols. However, one concern regarding PCA and OPLS is that
they are not discriminating statistical tests but analytical tools.
They will not provide a “yes” or “no” answer to questions of
comparability or equivalence of profiles. However, certain
parameters derived from these analyses may serve as criteria
for comparability or equivalence evaluation.
CONCLUSION
Aerosol delivery of drug provides a unique opportunity
in the prevention and/or treatment of invasive fungal
infections. Pulmonary delivery of antifungal agents may
increase local concentrations of the drug at the site where
many fungal pathogens gain entry into the body and establish
invasive infection. In the present study, both Acorn II and LC
Plus are suitable nebulizers for pulmonary delivery of
micafungin in terms of FPF and MMAD. However, a much
greater understanding of nebulizers, efficiency of delivery,
and local drug deposition is required for this approach to gain
general acceptance. Although their potential use as an APSD
profile comparator requires much greater study before their
application can be generally recommended, multivariate data
analysis such as PCA and OPLS are good pattern recognition
tools and offer scientists a useful mechanism by which to
evaluate APSD profiles generated with different nebulizers.
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